Klaus Podar

18.1k total citations · 3 hit papers
186 papers, 12.8k citations indexed

About

Klaus Podar is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Klaus Podar has authored 186 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Molecular Biology, 129 papers in Hematology and 64 papers in Oncology. Recurrent topics in Klaus Podar's work include Multiple Myeloma Research and Treatments (121 papers), Protein Degradation and Inhibitors (34 papers) and Ubiquitin and proteasome pathways (30 papers). Klaus Podar is often cited by papers focused on Multiple Myeloma Research and Treatments (121 papers), Protein Degradation and Inhibitors (34 papers) and Ubiquitin and proteasome pathways (30 papers). Klaus Podar collaborates with scholars based in United States, Germany and Austria. Klaus Podar's co-authors include Kenneth C. Anderson, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Nikhil C. Munshi, Constantine S. Mitsiades, Noopur Raje, Yu‐Tzu Tai, Martin Sattler and Nicholas Mitsiades and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Klaus Podar

183 papers receiving 12.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 560 citations Dharminder Chauhan, Klaus Podar et al. profile →
Multiple myeloma

2009 533 citations Marc S. Raab, Klaus Podar et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Klaus Podar	8.7k	6.6k	4.6k	1.8k	1.3k	186	12.8k
Robert Z. Orlowski	13.2k 1.5×	9.7k 1.5×	8.3k 1.8×	1.5k 0.8×	1.4k 1.1×	514	18.6k
Nicholas Mitsiades	10.1k 1.2×	4.6k 0.7×	4.5k 1.0×	1.9k 1.0×	2.4k 1.8×	172	15.3k
Constantine S. Mitsiades	14.1k 1.6×	9.5k 1.5×	7.3k 1.6×	2.4k 1.3×	2.2k 1.7×	296	20.0k
William S. Dalton	6.8k 0.8×	2.4k 0.4×	5.7k 1.3×	2.3k 1.2×	2.3k 1.8×	132	11.8k
Craig T. Jordan	10.2k 1.2×	6.6k 1.0×	4.5k 1.0×	3.0k 1.6×	3.6k 2.8×	237	17.3k
Martin Carroll	6.8k 0.8×	4.7k 0.7×	2.6k 0.6×	1.8k 1.0×	2.3k 1.8×	200	11.7k
Martin Sattler	4.3k 0.5×	3.1k 0.5×	2.4k 0.5×	1.2k 0.7×	764 0.6×	151	8.6k
Pierfrancesco Tassone	7.5k 0.9×	2.9k 0.4×	3.9k 0.9×	1.6k 0.9×	3.8k 2.9×	317	11.8k
Stefan N. Constantinescu	5.6k 0.6×	4.5k 0.7×	3.1k 0.7×	1.9k 1.0×	622 0.5×	172	11.3k
Victoria M. Richon	20.3k 2.4×	2.6k 0.4×	5.2k 1.1×	1.4k 0.8×	1.4k 1.1×	123	23.0k

Countries citing papers authored by Klaus Podar

Since Specialization

Citations

This map shows the geographic impact of Klaus Podar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Podar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Podar more than expected).

Fields of papers citing papers by Klaus Podar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Podar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Podar. The network helps show where Klaus Podar may publish in the future.

Co-authorship network of co-authors of Klaus Podar

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Podar. A scholar is included among the top collaborators of Klaus Podar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Podar. Klaus Podar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lütgendorf‐Caucig, Carola, et al.. (2025). PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Molecular Medicine. 17(5). 872–888. 4 indexed citations

Witalisz‐Siepracka, Agnieszka, et al.. (2025). Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia. Cancer Letters. 613. 217501–217501.

Neuditschko, Benjamin, Klaus Hackner, Franz Herzog, et al.. (2024). Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation. Journal for ImmunoTherapy of Cancer. 12(5). e008669–e008669. 6 indexed citations

Lind, Judith, Michaela Prchal‐Murphy, Fengjuan Fan, et al.. (2024). Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity. Blood Cancer Journal. 14(1). 138–138. 3 indexed citations

Stadlbauer, Andreas, Thomas M. Kinfe, Ilker Y. Eyüpoglu, et al.. (2020). Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Clinical Cancer Research. 27(6). 1641–1649. 24 indexed citations

Bashari, Muhammad Hasan, Fengjuan Fan, Sonia Vallet, et al.. (2016). Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Research. 18(1). 26–26. 29 indexed citations

Raab, Marc S., Iris Breitkreutz, Simon Anderhub, et al.. (2012). GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research. 72(20). 5374–5385. 56 indexed citations

Reddy, Mamatha M., Nicole J. Croteau, Christoph Walz, et al.. (2010). Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. Journal of Biological Chemistry. 285(42). 32596–32605. 39 indexed citations

Soydan, Ender, Wentao Song, Mariateresa Fulciniti, et al.. (2010). CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Blood (2009) 113, 18, (4309-4318)). Blood. 115(14). 5 indexed citations

10.

Zhang, Jing, Martin Sattler, Giovanni Tonon, et al.. (2009). Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma. Cancer Research. 69(12). 5082–5090. 76 indexed citations

11.

Podar, Klaus, Marc S. Raab, Giovanni Tonon, et al.. (2007). Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. Cancer Research. 67(4). 1680–1688. 55 indexed citations

12.

Tai, Yu‐Tzu, Xianfeng Li, Laurence Catley, et al.. (2005). Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. Cancer Research. 65(24). 11712–11720. 132 indexed citations

13.

Hideshima, Teru, Dharminder Chauhan, Toshiaki Hayashi, et al.. (2003). Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.. PubMed. 63(23). 8428–36. 58 indexed citations

14.

Podar, Klaus, Gustavo Mostoslavsky, YT Tai, et al.. (2003). Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin-6-induced proliferation and survival of multiple myeloma cells.. Blood. 102(11). 1 indexed citations

15.

Chauhan, D, Klaus Podar, Teru Hideshima, et al.. (2003). Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells.. Blood. 102(11). 2 indexed citations

16.

Tai, YT, Klaus Podar, Reshma Shringarpure, et al.. (2003). Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.. Blood. 102(11). 33 indexed citations

17.

Shringarpure, Reshma, D Chauhan, Renate Burger, et al.. (2003). Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications.. Blood. 102(11). 1 indexed citations

18.

Chauhan, D, Teru Hideshima, Klaus Podar, et al.. (2002). Heat shock protein-27 confers drug-resistance in multiple myeloma cells.. Blood. 100(11). 2 indexed citations

19.

Tai, Yu‐Tzu, Klaus Podar, Stine‐Kathrein Kraeft, et al.. (2002). Translocation of Ku86/Ku70 to the multiple myeloma cell membrane. Experimental Hematology. 30(3). 212–220. 31 indexed citations

20.

Gupta, Tapas K. Das, Richard LeBlanc, Klaus Podar, et al.. (2001). beta-Lapachone is safe and effective in Biege-Nude-Xid mouse xenograft model of human plasmacytoma.. Blood. 98(11). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact